SCHEMBL2826388

SCHEMBL2826388

COc1cccc(C=Cc2nc3sccn3c2C(=O)O)c1OCC1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACMSD Q8TDX5 2/20 0.39
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 3/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
TPH1 P17752 1/20 0.36
NFE2L2 Q16236 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
TRPM8 Q7Z2W7 2/20 0.34
PDE4D Q08499 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2826386 1.00 ACMSD (0.39) ACMSDALDH1A1KDM4EKMT2ANPC1
SCHEMBL2825383 0.90 MAPK1 (0.45) ACMSDALDH1A1KDM4EKMT2ANPC1
SCHEMBL2825379 0.90 MAPK1 (0.45) ACMSDALDH1A1KDM4EKMT2ANPC1
SCHEMBL13345822 0.87 ACMSD (0.36) ACMSDALDH1A1KDM4EKMT2ANPC1
SCHEMBL2824665 0.86 PDE4B (0.33) PDE4D
SCHEMBL2824662 0.86 PDE4B (0.33) PDE4D
SCHEMBL2368257 0.86 ACMSD (0.38) ACMSDALDH1A1KDM4EKMT2ANPC1
SCHEMBL2824763 0.86 ACMSD (0.38) ACMSDALDH1A1KDM4EKMT2ANPC1
SCHEMBL2824759 0.86 ACMSD (0.38) ACMSDALDH1A1KDM4EKMT2ANPC1
SCHEMBL2368260 0.86 ACMSD (0.38) ACMSDALDH1A1KDM4EKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318928-B2 Fused imidazole carboxamides as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-11-27 US disclosed
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A (CH) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV2 ACMSD 1516/4885ALDH1A1 2705/4885KDM4E 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.